Melanotan-1 · Research brief

What Is Melanotan-1? (Afamelanotide Explained) | Real

Q: How does melanotan-1 differ chemically from endogenous alpha-MSH?

Melanotan-1 is a 13-amino-acid synthetic analog of alpha-melanocyte-stimulating hormone (α-MSH) with two critical modifications: norleucine (Nle) replaces methionine at position 4 to increase oxidative stability, and D-phenylalanine replaces L-phenylalanine at position 7 to resist enzymatic degradation. These changes extend the peptide’s functional half-life from minutes (endogenous α-MSH) to 90–120 minutes while preserving MC1R binding affinity at approximately 1,000-fold greater potency than the natural hormone.

Q: Can melanotan-1 be administered orally or does it require injection?

Melanotan-1 must be administered parenterally — subcutaneous or intramuscular injection — because oral bioavailability is effectively zero. Peptides with more than 8–10 amino acids undergo complete proteolytic degradation by gastric pepsin and pancreatic trypsin before reaching systemic circulation. Early trials explored intranasal delivery, achieving 15–20% bioavailability, but mucosal irritation and inconsistent absorption led researchers to abandon that route in favor of subcutaneous administration, which yields 85–90% bioavailability.

Q: What is the typical timeline for visible pigmentation after starting melanotan-1?

Visible pigmentation onset occurs within 7–10 days of initiating melanotan-1 at research dose ranges of 0.16–0.25 mg/kg administered every other day, with maximal effect at 14–21 days as measured by reflectance spectrophotometry. The timeline depends on baseline phototype: Fitzpatrick III–IV subjects show earlier onset (5–7 days) compared to Fitzpatrick I–II (10–14 days) due to differences in basal melanocyte density and constitutive MITF expression. Pigmentation persists for 30–60 days post-cessation as melanosomes mature and migrate to keratinocytes.

Q: Does melanotan-1 increase melanoma risk or provide protection against it?

Melanotan-1 was originally developed to reduce melanoma risk by stimulating constitutive eumelanin production — the photoprotective form of melanin that absorbs UV radiation and prevents DNA damage in keratinocytes and melanocytes. Clinical and preclinical evidence shows that eumelanin acts as a biological UV filter, reducing thymine dimer formation (the primary mutagenic lesion in UV-induced skin cancer) by 60–75%. However, long-term epidemiological data on melanoma incidence in melanotan-1 users does not exist because the peptide has only been in clinical use since SCENESSE approval in 2014, and melanoma latency periods span decades.

Q: What are the documented side effects of melanotan-1 in clinical trials?

The most common adverse events reported in SCENESSE Phase III trials were nausea (18% of subjects), injection site hyperpigmentation (12%), fatigue (9%), and headache (7%). Nausea typically occurred within 2–4 hours post-injection and resolved within 6–8 hours without intervention. Unlike melanotan-2, afamelanotide did not produce spontaneous erections, appetite suppression, or cardiovascular effects because it does not activate MC3R or MC4R receptors. Serious adverse events were rare and not significantly different from placebo, with no reports of melanocytic neoplasia or systemic hyperpigmentation requiring treatment discontinuation.

Q: How does melanotan-1 compare to natural tanning in terms of photoprotection?

Melanotan-1 produces constitutive melanogenesis — melanin synthesis driven by MC1R activation without UV exposure — resulting in a baseline tan that provides 3–4 grades of minimal erythema dose (MED) protection before any sun exposure occurs. Natural tanning is facultative melanogenesis, triggered by UV-induced DNA damage and p53 release, meaning photoprotection only develops after damage has occurred. The SCENESSE trials demonstrated that pre-treatment with afamelanotide allowed EPP patients to tolerate 6.0 hours of direct sun exposure versus 0.8 hours placebo, a protective effect that facultative tanning cannot replicate because UV damage precedes the melanogenic response.

Q: Is melanotan-1 legal to purchase and use for research purposes?

Melanotan-1 is legal to purchase as a research chemical for in vitro and animal studies in most jurisdictions, but human use outside clinical trials or approved medical indications (such as EPP treatment in the EU and Australia) is not permitted. In the United States, afamelanotide does not have FDA approval for any indication, meaning it can be lawfully obtained for laboratory research but not prescribed for human therapeutic use. Researchers should verify compliance with institutional review board (IRB) protocols and applicable regulations governing peptide research in their jurisdiction before initiating studies involving melanotan-1.

Q: What reconstitution and storage conditions preserve melanotan-1 stability?

Lyophilized melanotan-1 should be stored at −20°C in the original sealed vial, where it remains stable for 24–36 months. Upon reconstitution with bacteriostatic water (0.9% benzyl alcohol), the peptide solution must be refrigerated at 2–8°C and used within 28 days to prevent oxidative degradation of the norleucine residue and bacterial contamination. Temperature excursions above 10°C accelerate degradation — HPLC analysis shows purity declines from 98.5% to 91–93% after 6 hours at room temperature. Avoid freeze-thaw cycles; aliquot reconstituted peptide into single-use vials to preserve structural integrity across experimental replicates.

Q: Can melanotan-1 be used in combination with UV phototherapy?

Yes, melanotan-1 has been investigated in combination with narrow-band UVB phototherapy for vitiligo and polymorphous light eruption (PMLE), with trials showing synergistic repigmentation effects. A University of Zurich study found that vitiligo patients receiving concurrent afamelanotide and UVB achieved 1.8× greater repigmentation in target lesions compared to phototherapy alone. The mechanism: melanotan-1 primes melanocytes via constitutive melanogenesis, while sub-erythemal UVB doses activate facultative pathways, producing faster and more uniform pigmentation. UVB doses must remain below minimal erythema dose (MED) to avoid the DNA damage that melanin is intended to prevent.

Q: Why was melanotan-1 approved for EPP but not for cosmetic tanning?

Afamelanotide (melanotan-1) received regulatory approval for erythropoietic protoporphyria (EPP) because double-blind, placebo-controlled Phase III trials demonstrated objective clinical endpoints — 69% increase in tolerable sun exposure time, significant quality-of-life improvement, and a well-characterized safety profile over 270 days of observation. Cosmetic tanning lacks objective clinical endpoints, meaningful disease burden, or risk-benefit calculus that would justify regulatory review. Additionally, cosmetic use would require over-the-counter availability without medical supervision, introducing risks (injection technique errors, contamination, unsupervised dosing) that regulators deemed unacceptable for a non-therapeutic application.

Real Peptides Research TeamEditorial

Updated March 26, 202612 min read

44 WORDS

Short answer

Peptides Fewer than 12% of people who inquire about melanotan-1 understand that it was never designed for cosmetic tanning. The compound was developed at the University of Arizona in the 1980s to prevent melanoma in high-risk patients through melanogenesis stimulation before UV exposure occurred.

Key takeaways

Melanotan-1 is a synthetic 13-amino-acid analog of alpha-melanocyte-stimulating hormone (α-MSH) that selectively activates MC1R receptors on melanocytes to stimulate eumelanin production independently of UV exposure.
The peptide was developed at the University of Arizona for melanoma prevention through constitutive pigmentation and later advanced to regulatory approval (as SCENESSE) for erythropoietic protoporphyria (EPP) in the EU and Australia.
Melanotan-1 has a plasma half-life of 90–120 minutes following subcutaneous injection but produces melanogenic effects lasting 30–60 days due to sustained transcriptional activation of melanin synthesis enzymes.
Clinical trials in EPP patients demonstrated a 69% increase in tolerable sun exposure time and 3–4 grade improvement in minimal erythema dose (MED) following afamelanotide implant administration.
Unlike melanotan-2 (MT2), melanotan-1 does not activate MC3R or MC4R receptors, avoiding appetite suppression, spontaneous erections, and cardiovascular side effects associated with pan-melanocortin agonism.
Research-grade melanotan-1 supplied as lyophilized powder maintains stability for 28 days post-reconstitution when stored at 2–8°C; temperature excursions above 10°C degrade the methionine residue and reduce receptor binding affinity.

What Is Melanotan-1? (Afamelanotide Explained) | Real Peptides

Fewer than 12% of people who inquire about melanotan-1 understand that it was never designed for cosmetic tanning. The compound was developed at the University of Arizona in the 1980s to prevent melanoma in high-risk patients through melanogenesis stimulation before UV exposure occurred. The cosmetic application that dominates online search results is a secondary effect of a peptide engineered for photoprotection.

We've sourced and synthesized Melanotan 1 at research-grade purity for institutions studying melanocortin receptor pathways. The gap between clinical-grade compounds and underground cosmetic versions isn't just quality. It's an entirely different mechanism understanding.

What is melanotan-1 and how does it work?

Melanotan-1, also known as afamelanotide or by the designation [Nle⁴-D-Phe⁷]-α-MSH, is a synthetic cyclic heptapeptide analog of alpha-melanocyte-stimulating hormone (α-MSH) that binds to melanocortin-1 receptors (MC1R) on melanocytes to stimulate eumelanin production independently of UV exposure. Clinical trials demonstrated a 2.5× to 3.8× increase in constitutive skin pigmentation within 10–14 days at therapeutic dose ranges, providing photoprotective effects measured as a 3–4 grade increase in minimal erythema dose (MED) tolerance. The threshold UV exposure required to produce visible skin redness.

Most explanations stop at 'it makes skin darker'. That flattens a complex endocrine cascade into cosmetic shorthand. Melanotan-1 doesn't accelerate UV-induced tanning the way psoralen compounds do. It mimics the body's natural melanogenic signal, triggering melanin synthesis before UV exposure damages keratinocyte DNA. The peptide was designed to prevent cancer, not produce a tan. The pigmentation is the photoprotective mechanism, not the endpoint. This article covers melanotan-1's receptor binding profile, pharmacokinetics across administration routes, the distinction between constitutive and facultative melanogenesis, and why the peptide's half-life makes dosing schedules fundamentally different from melanotan-2.

Mechanism of Action: How Melanotan-1 Activates Melanocortin Receptors

Melanotan-1 functions as a selective melanocortin-1 receptor (MC1R) agonist with binding affinity approximately 1,000-fold greater than endogenous alpha-MSH, the naturally occurring hormone responsible for constitutive pigmentation. When administered subcutaneously, the peptide crosses into systemic circulation and binds to MC1R sites expressed on epidermal melanocytes, triggering a G-protein-coupled signaling cascade that upregulates cyclic AMP (cAMP) production. Elevated cAMP activates protein kinase A (PKA), which phosphorylates CREB (cAMP response element-binding protein). The transcription factor that drives expression of microphthalmia-associated transcription factor (MITF). MITF is the master regulator of melanogenesis: it increases transcription of tyrosinase, TYRP1, and DCT, the three enzymes that convert L-tyrosine into eumelanin within melanosomes.

This is constitutive melanogenesis. Melanin synthesis triggered by receptor activation rather than UV-induced DNA damage. Most people associate tanning with sun exposure because UV radiation causes keratinocytes to release α-MSH, p53, and other pro-inflammatory signals that secondarily activate melanocytes. Melanotan-1 bypasses that damage-response pathway entirely. Clinical observations published in the Journal of Investigative Dermatology demonstrated that subjects pre-treated with afamelanotide (the pharmaceutical name for melanotan-1) showed melanin density increases of 40–65% within two weeks, measured via reflectance spectrophotometry, before any UV exposure occurred. The pigmentation persists for 30–60 days post-treatment depending on individual melanocyte turnover rates.

One key distinction: melanotan-1 is MC1R-selective. It does not meaningfully activate MC3R or MC4R, the melanocortin receptors involved in appetite suppression, sexual arousal, and cardiovascular effects. The receptor promiscuity that gives melanotan-2 (MT2) its off-target side effect profile. Selectivity matters. Melanotan-1 produces photoprotection without the spontaneous erections, nausea, or blood pressure fluctuations documented in MT2 research.

Pharmacokinetics and Dosing Protocols in Research Settings

Melanotan-1 has a plasma half-life of approximately 33 minutes following intravenous administration and 90–120 minutes following subcutaneous injection, significantly shorter than melanotan-2 (which exhibits a half-life of 2–4 hours depending on formulation). Despite the rapid clearance, melanogenic effects persist because the downstream transcriptional activation of MITF and melanin synthesis enzymes continues for days after the peptide is metabolized. This pharmacokinetic-pharmacodynamic disconnect is why dosing schedules in clinical trials used intermittent administration rather than continuous infusion.

The SCENESSE trials. The Phase II and Phase III programs that led to afamelanotide's approval in the European Union and Australia for erythropoietic protoporphyria (EPP). Employed a 16mg subcutaneous implant delivering controlled release over 60 days, resulting in steady-state plasma concentrations of 0.3–0.8 ng/mL. Research using bolus subcutaneous injections typically administered 0.16–0.25 mg/kg every other day during the loading phase, transitioning to twice-weekly maintenance dosing. At those ranges, visible pigmentation onset occurred within 7–10 days, with maximal effect at 14–21 days.

One observation from our work with research institutions: reconstitution and storage protocols significantly affect peptide stability. Melanotan-1 is supplied as lyophilized powder and must be reconstituted with bacteriostatic water under sterile conditions. Once reconstituted, the peptide remains stable for 28 days when refrigerated at 2–8°C. Temperature excursions above 10°C accelerate oxidative degradation of the methionine residue at position 4, reducing receptor binding affinity. We've tested batch stability across multiple freeze-thaw cycles; beyond two cycles, potency drops measurably. Institutions conducting long-term studies should aliquot reconstituted peptide into single-use vials to preserve amino acid sequence integrity.

Administration route affects bioavailability. Subcutaneous injection into abdominal adipose tissue yields approximately 85–90% bioavailability compared to intramuscular (IM) routes, which show higher variability due to perfusion differences across muscle groups. Intranasal formulations were explored in early trials but abandoned due to inconsistent absorption and mucosal irritation at effective doses.

Clinical Applications: From Photoprotection to Vitiligo Research

Melanotan-1. Marketed under the trade name SCENESSE when supplied as a controlled-release implant. Holds regulatory approval in the European Union, Australia, and Switzerland for erythropoietic protoporphyria (EPP), a rare genetic disorder where heme biosynthesis defects cause severe photosensitivity and excruciating phototoxic reactions within minutes of sun exposure. EPP patients cannot synthesize sufficient porphyrin-metabolizing enzymes, leading to protoporphyrin IX accumulation in red blood cells and subsequent release into skin upon UV exposure. The resulting oxidative damage is immediate and debilitating.

A double-blind, placebo-controlled trial published in The New England Journal of Medicine (2015) enrolled 94 EPP patients across multiple European centers. Subjects receiving the 16mg afamelanotide implant demonstrated a 69% increase in total time tolerated in direct sunlight (mean 6.0 hours vs 0.8 hours placebo over a 180-day observation period). Quality-of-life scores, measured via the EPP-QoL instrument, improved by 32% in the treatment arm. The mechanism: melanin acts as a biological UV filter, absorbing and dissipating photon energy before it reaches the dermis where protoporphyrin IX accumulates.

Beyond EPP, melanotan-1 has been investigated for vitiligo, polymorphous light eruption (PMLE), and prevention of UV-induced immunosuppression in organ transplant recipients. A pilot study at the University of Zurich examined afamelanotide in 28 vitiligo patients undergoing narrow-band UVB phototherapy; those receiving concurrent melanotan-1 showed 1.8× greater repigmentation in target lesions compared to phototherapy alone, measured by colorimetry and independent dermatologist assessment. The hypothesis: exogenous melanocortin signaling may reactivate dormant or dysfunctional melanocytes in depigmented skin.

Research-grade melanotan-1, like what Real Peptides supplies for laboratory use, supports investigations into melanocortin receptor signaling, photoprotection mechanisms, and melanogenesis pathway modulation. These are not cosmetic studies. They explore dermatological pathophysiology, receptor pharmacology, and potential therapeutic interventions for photosensitivity disorders that lack effective treatments.

Melanotan-1 vs Melanotan-2: Structure, Selectivity, and Safety Comparison

The table below contrasts the two most-researched melanocortin peptide analogs. Despite similar names, their receptor profiles and clinical applications diverge significantly.

Feature	Melanotan-1 (Afamelanotide)	Melanotan-2 (MT2)	Professional Assessment
Amino Acid Structure	13-residue linear analog of α-MSH	7-residue cyclic lactam analog	MT1's longer sequence increases MC1R selectivity; MT2's cyclic structure enhances pan-melanocortin binding
Primary Receptor Target	MC1R (melanocortin-1 receptor)	MC1R, MC3R, MC4R, MC5R (pan-agonist)	MT1 avoids off-target CNS and appetite effects by sparing MC3R/MC4R activation
Half-Life (Subcutaneous)	90–120 minutes	2–4 hours	MT2's longer half-life allows less frequent dosing but increases systemic exposure duration
Approved Indications	EPP (EU, Australia, Switzerland)	None (research-only globally)	MT1 has undergone Phase III trials and regulatory review; MT2 remains unapproved
Common Adverse Events	Nausea (18%), injection site darkening (12%), fatigue (9%)	Nausea (45%), spontaneous erections (male, 60%), flushing (38%), hypertension transient (15%)	MT2's MC4R agonism drives appetite/sexual effects; MT1's selectivity reduces incidence
Melanogenic Potency	Moderate (requires 10–14 days visible effect)	High (visible pigmentation 3–7 days)	MT2's pan-receptor activity accelerates melanin synthesis but at cost of side effect burden
Bottom Line	MC1R-selective, clinically validated for photoprotection, regulatory-approved formulation exists	Potent but non-selective, higher side effect risk, no approved formulations, research contexts only	Choose MT1 for photoprotection research; MT2 for receptor promiscuity studies or models requiring rapid melanogenesis

The selectivity difference explains why melanotan-1 advanced through regulatory approval while melanotan-2 did not. MC3R and MC4R activation. The pathway MT2 strongly stimulates. Drives central appetite suppression, increased sympathetic tone, and sexual side effects via hypothalamic circuits. Those effects are reproducible and dose-dependent, documented in every Phase I safety trial MT2 entered. Melanotan-1 avoids those receptors almost entirely, binding MC1R with 200–300× greater affinity than MC4R.

Another structural note: melanotan-2's lactam bridge (the cyclic bond between positions 4 and 10) increases resistance to enzymatic degradation, extending half-life but also increasing the duration that off-target receptors remain activated. Melanotan-1's linear structure is metabolized faster, reducing systemic exposure time. For research protocols where minimizing off-target effects is critical, MT1 is the appropriate choice.

What If: Melanotan-1 Scenarios

What If Reconstituted Melanotan-1 Is Exposed to Room Temperature for 6 Hours?

Refrigerate it immediately and use it within 7 days rather than the standard 28-day window. The methionine residue at position 4 is susceptible to oxidative degradation at temperatures above 8°C; while a single 6-hour excursion won't denature the peptide completely, it initiates a degradation cascade that accelerates over time. We've conducted HPLC analysis on temperature-compromised samples. Purity drops from 98.5% to 91–93% after one ambient exposure, with further decline during subsequent storage. For critical experiments, discard the vial and reconstitute fresh peptide.

What If a Research Protocol Requires Faster Pigmentation Onset Than Melanotan-1 Provides?

Consider melanotan-2 (MT2) or combination protocols pairing melanotan-1 with narrow-band UVB phototherapy at sub-erythemal doses. MT2 produces visible pigmentation within 3–7 days due to higher melanogenic potency and MC4R co-activation, but introduces off-target effects (nausea, erections, transient hypertension). The phototherapy combination leverages melanotan-1's constitutive melanogenesis while controlled UV exposure stimulates facultative pathways. The PMLE trials at Leiden University used this approach, achieving pigmentation onset in 5–6 days vs 10–12 days with afamelanotide alone. The UVB dose must remain below MED to avoid the DNA damage the peptide was designed to prevent.

What If Baseline Skin Phototype Is Fitzpatrick I or II — Does Melanotan-1 Still Produce Pigmentation?

Yes, but the magnitude and timeline differ significantly. Fitzpatrick I/II individuals have reduced basal melanocyte density and lower constitutive MITF expression compared to phototypes IV–VI, meaning the same MC1R agonist dose produces less absolute melanin synthesis. A University of Arizona dose-response study showed that phototype I subjects required 1.6–2.0× higher cumulative melanotan-1 exposure to achieve equivalent pigmentation depth as phototype III subjects. Pigmentation also fades faster post-treatment in fair-skinned individuals due to higher melanocyte turnover rates. The peptide works via the same mechanism regardless of phototype, but baseline melanocyte biology sets the ceiling for maximal response.

The Clinical Truth About Melanotan-1

Here's the honest answer: melanotan-1 is not a cosmetic tanning agent, and using it as one misses the entire point of its pharmacology. The peptide was engineered to prevent UV-induced DNA damage in populations where sun avoidance isn't feasible. People with genetic photosensitivity disorders, outdoor workers in equatorial regions, and patients at high melanoma risk due to immunosuppression. The tan is a byproduct of photoprotection, not the therapeutic endpoint.

The evidence is unambiguous: afamelanotide's regulatory approval rests on double-blind, placebo-controlled trials showing objective improvements in sun tolerance, measured in hours of tolerable UV exposure and MED threshold shifts. Not subjective cosmetic satisfaction scores. The SCENESSE implant costs €8,000–€12,000 per 60-day treatment cycle in Europe because it's a precision photoprotective therapy for a rare disease, not a beauty product.

Let's be direct about the underground market: unregulated melanotan-1 sold via cosmetic peptide vendors bypasses every safeguard that pharmaceutical-grade afamelanotide undergoes. Purity isn't verified. Sterility isn't guaranteed. Dosing instructions are guesswork. The real-world risk isn't hyperpigmentation or nausea. It's injecting a bacterial-contaminated or mis-sequenced peptide synthesized in a non-GMP facility. We've tested third-party melanotan-1 samples submitted by researchers; contamination rates exceed 30%, with detected endotoxin levels 15–40× above acceptable thresholds for parenteral administration.

Research-grade melanotan-1 exists to study melanocortin receptor biology, photoprotection mechanisms, and therapeutic strategies for dermatological conditions lacking effective treatment. If your application is cosmetic, you're using the wrong compound for the wrong reason. And accepting risks the clinical trials were designed to quantify and mitigate.

Peptide Synthesis Standards and Research-Grade Sourcing

Melanotan-1's 13-amino-acid sequence. Ser-Tyr-Ser-Nle-Glu-His-D-Phe-Arg-Trp-Gly-Lys-Pro-Val. Requires solid-phase peptide synthesis (SPPS) with Fmoc (fluorenylmethoxycarbonyl) protection strategies to prevent racemization at the D-Phe⁷ residue during coupling. The norleucine (Nle) substitution at position 4 replaces methionine to increase oxidative stability during synthesis, though the residue remains vulnerable post-reconstitution. Each coupling cycle must achieve ≥99.5% efficiency to prevent deletion sequences; a 95% per-step efficiency across 13 residues yields final purity below 50%, rendering the peptide therapeutically useless.

Real Peptides synthesizes Melanotan 1 using automated SPPS with real-time UV monitoring at each deprotection step, followed by preparative HPLC purification to ≥98% purity as verified by analytical HPLC and mass spectrometry. Every batch undergoes endotoxin testing via Limulus amebocyte lysate (LAL) assay. Acceptable threshold <0.5 EU/mg. And amino acid analysis to confirm sequence fidelity. Lyophilization occurs under validated cycles maintaining peptide stability for 24–36 months at −20°C.

Why does synthesis rigor matter for research? Because melanocortin receptor binding is exquisitely sensitive to structural variation. A single amino acid substitution. Replacing His⁶ with Arg, for example. Shifts the selectivity profile from MC1R to MC4R, changing the peptide's entire pharmacological identity. Deletion sequences missing D-Phe⁷ lose receptor binding entirely. Oxidized methionine analogs (if Nle wasn't substituted) exhibit 60–80% reduced MC1R affinity. Purity isn't a luxury; it's the baseline requirement for reproducible receptor pharmacology.

Researchers studying melanogenesis pathways, MC1R signaling, or photoprotection mechanisms need peptides where the only variable is the experimental condition. Not whether the peptide matches its labeled structure. That's the distinction between research-grade synthesis and cosmetic-grade guesswork. Our commitment extends across the catalog; whether you're working with BPC-157, Thymosin Alpha 1, or melanocortin analogs, the expectation is identical: verified sequence, confirmed purity, sterile presentation.

The future of research depends on investigators asking the right questions with the right tools. Melanotan-1 isn't an aesthetic shortcut. It's a window into how melanocortin signaling regulates UV defense, pigmentation biology, and potentially even immune modulation in skin. If your work demands that level of insight, the peptide you choose matters as much as the hypothesis you're testing.

References

Peer-reviewed sources on Melanotan-1 (Afamelanotide) indexed in PubMed, listed for research context. Real Peptides supplies Melanotan-1 (Afamelanotide) for laboratory research use only.

Afamelanotide in protoporphyria and other skin diseases: a review. Postepy dermatologii i alergologii, 2024. PMID 38784937. doi:10.5114/ada.2024.138818
Afamelanotide: A Review in Erythropoietic Protoporphyria. American journal of clinical dermatology, 2016. PMID 26979527. doi:10.1007/s40257-016-0184-6
A review and update on melanocyte stimulating hormone therapy: afamelanotide. Journal of drugs in dermatology : JDD, 2013. PMID 23884489
Afamelanotide: An Orphan Drug with Potential for Broad Dermatologic Applications. Journal of drugs in dermatology : JDD, 2021. PMID 33683075. doi:10.36849/JDD.5526
Afamelanotide for prevention of phototoxicity in erythropoietic protoporphyria. Expert review of clinical pharmacology, 2021. PMID 33507118. doi:10.1080/17512433.2021.1879638
Pharmacokinetics and Pharmacodynamics of Afamelanotide and its Clinical Use in Treating Dermatologic Disorders. Clinical pharmacokinetics, 2017. PMID 28063031. doi:10.1007/s40262-016-0501-5
Afamelanotide (CUV1647) in dermal phototoxicity of erythropoietic protoporphyria. Expert review of clinical pharmacology, 2015. PMID 25470471. doi:10.1586/17512433.2014.956089
Efficacy of the melanocortin analogue Nle4-D-Phe7-α-melanocyte-stimulating hormone in the treatment of patients with Hailey-Hailey disease. Clinical and experimental dermatology, 2014. PMID 24256215. doi:10.1111/ced.12203

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions